Abstract
Purpose
Betanin is a betacyanin with antioxidant and anti-inflammatory activities whose effects were investigated in a nonalcoholic steatohepatitis (NASH) model.
Main methods
Ninety-six male naval medical research institute (NMRI) mice were divided into eight groups (n = 12) including normal control, high fat diet (HFD), Sham, and positive control treated with trans-chalcone. Three experimental groups were treated with 5 mg/kg, 10 mg/kg or 20 mg/kg betanin, and a betanin protective group was also defined.
Results
Four weeks of HFD treatment resulted in steatohepatitis with associated fibrosis. Significant increase was observed in serum levels of triglycerides (TG), total cholesterol (TC), glucose, insulin, leptin, liver enzymes, malondialdehyde (MDA), furthermore insulin resistance and (sterol regulatory element-binding protein-1c) SREBP-1c were detected. Levels of high-density lipoprotein cholesterol (HDL-C), adiponectin, superoxide dismutase (SOD), catalase (CAT), and PPAR-α (peroxisome proliferator-activated receptor-α) considerably decreased. Treatment by betanin, particularly the 20 mg/kg dosage, attenuated these changes.
Conclusion
Betanin is a potential treating agent of steatohepatitis and works through up-regulation of PPAR-α, down-regulation of SREBP-1c, modification of adipokine levels and modulation of lipid profile.
Supplementary Materials
- Supplementary Material
- Supplementary Material
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Al-Busafi SA, Bhat M, Wong P, Ghali P, Deschenes M. Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat. 2012;2012:947575.
-
2.
Allegra M, Tesoriere L, Livrea MA. Betanin inhibits the myeloperoxidase/nitrite-induced oxidation of human low-density lipoproteins. Free Radic Res. 2007;41:335–41.
-
3.
Bjerre-Harpøth V, Storm AC, Eslamizad M, Kuhla B, Larsen M. Effect of propylene glycol on adipose tissue mobilization in postpartum over-conditioned Holstein cows. J. Dairy Sci. 2015;98:8581–96.
-
4.
Burri L, Thoresen GH, Berge RK. The role of PPAR activation in liver and muscle. PPAR Res. 2010;2010:542359.
-
5.
Chitturi S, Abeygunasekera S, Farrell GC, Holmes‐Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.
-
6.
Cho J-H, Namgung J-S, Lee J, Moon D-H, Lee H-K. Analysis of biochemical markers related to Fatty liver patients. J Phys Ther Sci. 2014;26:1865–8.
-
7.
Clifford T, Howatson G, West DJ, Stevenson EJ. The potential benefits of red beetroot supplementation in health and disease. Nutrients. 2015;7:2801-2822.
-
8.
Dowman JK, Tomlinson J, Newsome P. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71–83.
-
9.
El Gamal AA, AlSaid MS, Raish M, Al-Sohaibani M, Al-Massarani SM, Ahmad A, et al. Beetroot (Beta vulgaris L.) extract ameliorates gentamicin-induced nephrotoxicity associated oxidative stress, inflammation, and apoptosis in rodent model. Mediators Inflamm. 2014;2014:983952.
-
10.
Foretz M, Pacot C, Dugail I, Lemarchand P, Guichard C, le Lièpvre X, et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol. 1999;19:3760–8.
-
11.
Gliszczyńska-Świgło A, Szymusiak H, Malinowska P. Betanin, the main pigment of red beet: molecular origin of its exceptionally high free radical-scavenging activity. Food Addit Contam. 2006;23:1079–87.
-
12.
Hall P, Cash J. What is the real function of the liver ‘function’ tests? Ulster Med J. 2012;81:30–6.
-
13.
Han J, Ma D, Zhang M, Yang X, Tan D. Natural antioxidant betanin protects rats from paraquat-induced acute lung injury interstitial pneumonia. Biomed Res Int. 2015;2015:608174.
-
14.
Han J, Tan C, Wang Y, Yang S, Tan D. Betanin reduces the accumulation and cross-links of collagen in high-fructose-fed rat heart through inhibiting non-enzymatic glycation. Chem Biol Interact. 2015;227:37–44.
-
15.
Han J, Zhang Z, Yang S, Wang J, Yang X, Tan D. Betanin attenuates paraquat-induced liver toxicity through a mitochondrial pathway. Food Chem Toxicol. 2014;70:100–6.
-
16.
Jalalvand F, Amoli MM, Yaghmaei P, Kimiagar M, Ebrahim-Habibi A. Acarbose versus trans-chalcone: comparing the effect of two glycosidase inhibitors on obese mice. Arch. Endocrinol Metab. 2015;59:202–9.
-
17.
Karkhaneh L, Yaghmaei P, Parivar K, Sadeghizadeh M, Ebrahim-Habibi A. Effect of trans-chalcone on atheroma plaque formation, liver fibrosis and adiponectin gene expression in cholesterol-fed NMRI mice. Pharmacol Rep. 2016;68:720–7.
-
18.
Kleiner DE. Histopathology, grading and staging of nonalcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2018;64:28–38.
-
19.
Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007;20:351–8.
-
20.
Krajka-Kuźniak V, Paluszczak J, Szaefer H, Baer-Dubowska W. Betanin, a beetroot component, induces nuclear factor erythroid-2-related factor 2-mediated expression of detoxifying/antioxidant enzymes in human liver cell lines. Br J Nutr. 2013;110:2138–49.
-
21.
Lee J-H, Kang HS, Park HY, Moon Y-A, Kang YN, Oh B-C, et al. PPARα-dependent Insig2a overexpression inhibits SREBP-1c processing during fasting. Sci Rep. 2017;7:9958.
-
22.
Livrea MA, Tesoriere L. Lipoperoxyl radical scavenging and antioxidative effects of red beet pigments. In: Neelwarne B, editor. Red beet biotechnology. Boston, MA: Springer; 2013. pp. 105–24.
-
23.
Machado MV, Michelotti GA, Xie G, de Almeida TP, Boursier J, Bohnic B, et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One. 2015;10, e0127991
-
24.
Martinez RM, Longhi-Balbinot DT, Zarpelon AC, Staurengo-Ferrari L, Baracat MM, Georgetti SR, et al. Anti-inflammatory activity of betalain-rich dye of Beta vulgaris: effect on edema, leukocyte recruitment, superoxide anion and cytokine production. Arch Pharm Res. 2015;38:494–504.
-
25.
Murthy KNC, Manchali S. Anti-diabetic potentials of red beet pigments and other constituents. In: Neelwarne B, editor. Red beet biotechnology. Boston, MA: Springer; 2013. pp. 155–74.
-
26.
Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720–33.
-
27.
Pietrzkowski Z, Nemzer B, Spórna A, Stalica P, Tresher W, Keller R, et al. Influence of betalain-rich extract on reduction of discomfort associated with osteoarthritis. New Medicine. 2010;1:12–7.
-
28.
Prabhakar K, Afzal SM, Surender G, Kishan V. Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm Sin B. 2013;3:345–53.
-
29.
Qu H-Q, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB. The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PLoS One. 2011;6:e21041
-
30.
Ramli NS, Brown L, Ismail P, Rahmat A. Effects of red pitaya juice supplementation on cardiovascular and hepatic changes in high-carbohydrate, high-fat diet-induced metabolic syndrome rats. BMC Complement Altern Med. 2014;14:1.
-
31.
Rotunda AM, Suzuki H, Moy RL, Kolodney MS. Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol Surg. 2004;30:1001–8.
-
32.
Sárdi É, Stefanovits-Bányai É, Kocsis I, Takács-Hájos M, Fébel H, Blázovics A. Effect of bioactive compounds of table beet cultivars on alimentary induced fatty livers of rats. Acta Alimentaria. 2009;38:267–80.
-
33.
Song H, Chu Q, Xu D, Xu Y, Zheng X. Purified betacyanins from hylocereus undatus peel ameliorate obesity and insulin resistance in high-fat-diet-fed mice. J Agric Food Chem. 2015;64:236–44.
-
34.
Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol. 2015;7:1012–9.
-
35.
Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768–80.
-
36.
Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta. 2012;1821:809–18.
-
37.
Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6:456–80.
-
38.
Tsai PJ, Hsiao SM, Chaung HC, Hong CZ, Wang CL. The LDL-cholesterol-lowering Effects of Nano-particled Djulis Grains. In: Proceedings of International Conference on Bioscience, Biochemistry and Bioinformatics (ICBBB 2011). Singapore: IACSIT Press; 2011. pp. 218–21.
-
39.
Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm. 2009;2009:831670.
-
40.
Wroblewska M, Juskiewicz J, Wiczkowski W. Physiological properties of beetroot crisps applied in standard and dyslipidaemic diets of rats. Lipids Health Dis. 2011;10:1.
-
41.
Ziamajidi N, Khaghani S, Hassanzadeh G, Vardasbi S, Ahmadian S, Nowrouzi A, et al. Amelioration by chicory seed extract of diabetes-and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. Food Chem Toxicol. 2013;58:198–209.
-
42.
Zimmer M, Bista P, Benson EL, Lee DY, Liu F, Picarella D, et al. CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E∗ 3‐Leiden mice. Hepatol Commun. 2017;1:311–25.
Editor-in-Chief
László ROSIVALL (Semmelweis University, Budapest, Hungary)
Managing Editor
Anna BERHIDI (Semmelweis University, Budapest, Hungary)
Co-Editors
- Gábor SZÉNÁSI (Semmelweis University, Budapest, Hungary)
- Ákos KOLLER (Semmelweis University, Budapest, Hungary)
- Zsolt RADÁK (University of Physical Education, Budapest, Hungary)
- László LÉNÁRD (University of Pécs, Hungary)
- Zoltán UNGVÁRI (Semmelweis University, Budapest, Hungary)
Assistant Editors
- Gabriella DÖRNYEI (Semmelweis University, Budapest, Hungary)
- Zsuzsanna MIKLÓS (Semmelweis University, Budapest, Hungary)
- György NÁDASY (Semmelweis University, Budapest, Hungary)
Hungarian Editorial Board
- György BENEDEK (University of Szeged, Hungary)
- Zoltán BENYÓ (Semmelweis University, Budapest, Hungary)
- Mihály BOROS (University of Szeged, Hungary)
- László CSERNOCH (University of Debrecen, Hungary)
- Magdolna DANK (Semmelweis University, Budapest, Hungary)
- László DÉTÁRI (Eötvös Loránd University, Budapest, Hungary)
- Zoltán GIRICZ (Semmelweis University, Budapest, Hungary and Pharmahungary Group, Szeged, Hungary)
- Zoltán HANTOS (Semmelweis University, Budapest and University of Szeged, Hungary)
- László HUNYADI (Semmelweis University, Budapest, Hungary)
- Gábor JANCSÓ (University of Pécs, Hungary)
- Zoltán KARÁDI (University of Pecs, Hungary)
- Miklós PALKOVITS (Semmelweis University, Budapest, Hungary)
- Gyula PAPP (University of Szeged, Hungary)
- Gábor PAVLIK (University of Physical Education, Budapest, Hungary)
- András SPÄT (Semmelweis University, Budapest, Hungary)
- Gyula SZABÓ (University of Szeged, Hungary)
- Zoltán SZELÉNYI (University of Pécs, Hungary)
- Lajos SZOLLÁR (Semmelweis University, Budapest, Hungary)
- Gyula TELEGDY (MTA-SZTE, Neuroscience Research Group and University of Szeged, Hungary)
- József TOLDI (MTA-SZTE Neuroscience Research Group and University of Szeged, Hungary)
- Árpád TÓSAKI (University of Debrecen, Hungary)
International Editorial Board
- Dragan DJURIC (University of Belgrade, Serbia)
- Christopher H. FRY (University of Bristol, UK)
- Stephen E. GREENWALD (Blizard Institute, Barts and Queen Mary University of London, UK)
- Osmo Otto Päiviö HÄNNINEN (Finnish Institute for Health and Welfare, Kuopio, Finland)
- Helmut G. HINGHOFER-SZALKAY (Medical University of Graz, Austria)
- Tibor HORTOBÁGYI (University of Groningen, Netherlands)
- George KUNOS (National Institutes of Health, Bethesda, USA)
- Massoud MAHMOUDIAN (Iran University of Medical Sciences, Tehran, Iran)
- Tadaaki MANO (Gifu University of Medical Science, Japan)
- Luis Gabriel NAVAR (Tulane University School of Medicine, New Orleans, USA)
- Hitoo NISHINO (Nagoya City University, Japan)
- Ole H. PETERSEN (Cardiff University, UK)
- Ulrich POHL (German Centre for Cardiovascular Research and Ludwig-Maximilians-University, Planegg, Germany)
- Andrej A. ROMANOVSKY (University of Arizona, USA)
- Anwar Ali SIDDIQUI (Aga Khan University, Karachi, Pakistan)
- Csaba SZABÓ (University of Fribourg, Switzerland)
- Eric VICAUT (Université de Paris, UMRS 942 INSERM, France)
- Nico WESTERHOF (Vrije Universiteit Amsterdam, The Netherlands)
Editorial Office:
Akadémiai Kiadó Zrt.
Prielle Kornélia u. 21–35, H-1117 Budapest, Hungary
Editorial Correspondence:
Physiology International
Semmelweis University, Faculty of Medicine Institute of Pathophysiology
Nagyvárad tér 4, H-1089 Budapest, Hungary
Phone/Fax: +36-1-2100-100
E-mail: pi@semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- EMBASE/Excerpta Medica
- Global Health
- Index Copernicus
- Index Medicus
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Social Science Citation Index
| 2020 | |
| Total Cites | 245 |
| WoS | |
| Journal Impact Factor |
2,090 |
| Rank by | Physiology 62/81 (Q4) |
| Impact Factor | |
| Impact Factor | 1,866 |
| without | |
| Journal Self Cites | |
| 5 Year | 1,703 |
| Impact Factor | |
| Journal | 0,51 |
| Citation Indicator | |
| Rank by Journal | Physiology 67/84 (Q4) |
| Citation Indicator | |
| Citable | 42 |
| Items | |
| Total | 42 |
| Articles | |
| Total | 0 |
| Reviews | |
| Scimago | 29 |
| H-index | |
| Scimago | 0,417 |
| Journal Rank | |
| Scimago | Physiology (medical) Q3 |
| Quartile Score | |
| Scopus | 270/1140=1,9 |
| Scite Score | |
| Scopus | Physiology (medical) 71/98 (Q3) |
| Scite Score Rank | |
| Scopus | 0,528 |
| SNIP | |
| Days from | 172 |
| submission | |
| to acceptance | |
| Days from | 106 |
| acceptance | |
| to publication |
| 2019 | |
|---|---|
| Total Cites WoS |
137 |
| Impact Factor | 1,410 |
| Impact Factor without Journal Self Cites |
1,361 |
| 5 Year Impact Factor |
1,221 |
| Immediacy Index |
0,294 |
| Citable Items |
34 |
| Total Articles |
33 |
| Total Reviews |
1 |
| Cited Half-Life |
2,1 |
| Citing Half-Life |
9,3 |
| Eigenfactor Score |
0,00028 |
| Article Influence Score |
0,215 |
| % Articles in Citable Items |
97,06 |
| Normalized Eigenfactor |
0,03445 |
| Average IF Percentile |
12,963 |
| Scimago H-index |
27 |
| Scimago Journal Rank |
0,267 |
| Scopus Scite Score |
235/157=1,5 |
| Scopus Scite Score Rank |
Physiology (medical) 73/99 (Q3) |
| Scopus SNIP |
0,38 |
| Physiology International | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article |
| Printed Color Illustrations | 40 EUR (or 10 000 HUF) + VAT / piece |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2022 | Online subsscription: 644 EUR / 806 USD Print + online subscription: 752 EUR / 942 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Physiology International | |
|---|---|
| Language | English |
| Size | B5 |
| Year of Foundation |
2006 (1950) |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 2498-602X (Print) |
| ISSN | 2677-0164 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Sep 2021 | 71 | 2 | 2 |
| Oct 2021 | 56 | 2 | 2 |
| Nov 2021 | 66 | 1 | 2 |
| Dec 2021 | 56 | 1 | 0 |
| Jan 2022 | 62 | 4 | 2 |
| Feb 2022 | 56 | 0 | 0 |
| Mar 2022 | 4 | 0 | 0 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory